Situation: The Rural Health Unit (RHU) is planning community screening programs, and the nurse helps evaluate the screening tests. Before starting the diabetes screening, the team reviews the WHO (Wilson and Jungner) criteria for screening. Which is one of these criteria?

The Wilson and Jungner criteria require, among others, that the condition be an important health problem, that there be an accepted treatment and facilities for diagnosis and treatment, that there be a recognizable latent or early symptomatic stage, and that the test be suitable, acceptable, safe, and inexpensive. Screening without a treatment pathway only causes harm and anxiety.

The Wilson and Jungner criteria, first published by the World Health Organization in 1968, remain the foundational framework for deciding whether a population screening program is ethically and practically justified. Among the ten principles, the presence of an accepted treatment for individuals identified with the condition is a non-negotiable requirement. This is the correct answer because screening is only beneficial when an effective intervention can alter the disease trajectory after detection.

The core logic is that screening without a treatment pathway converts healthy-feeling people into patients without offering any clinical advantage, producing only anxiety, labeling, and unnecessary follow-up. Wilson and Jungner explicitly stated that there should be an accepted treatment for persons with recognized disease, along with facilities for diagnosis and treatment. The historical analysis of PHP-34 confirms that this principle was designed to prevent exactly the scenario described in the incorrect options: identifying a condition that cannot be acted upon ^[1].

The remaining options each violate a specific Wilson and Jungner principle. Option 2 states the disease is rare, but the criteria require the condition to be an important health problem—a rare disease may still qualify if it is serious, but rarity alone is not a screening justification. Option 3 prioritizes accuracy regardless of cost, yet the criteria demand that the test be acceptable, safe, and inexpensive; a perfect but unaffordable test fails the population-level feasibility standard. Option 4 claims there is no early stage, which directly contradicts the requirement for a recognizable latent or early symptomatic stage during which intervention is more effective than waiting for clinical presentation.

The contemporary relevance of the treatment criterion is illustrated by newborn screening for spinal muscular atrophy (SMA). Researchers note that SMA was historically excluded from newborn screening panels because no disease-modifying therapy existed. Once gene therapies became available—and were shown to be most efficacious when delivered pre-symptomatically—the case for screening rapidly gained momentum ^[2][3]. This real-world example demonstrates that the treatment criterion is not a static historical footnote but an active gatekeeper: screening programs are added or withheld based on whether an effective intervention now exists.

A similar dynamic appears in discussions about genomic sequencing in newborn screening. Stakeholders in the Netherlands recognized that expanding screening to include many genetic conditions raises the problem of detecting variants for which no treatment or preventive strategy is available. Such findings would violate the Wilson and Jungner framework and create ethical dilemmas about what to disclose to families . This reinforces why the treatment criterion remains central to screening policy decisions.

Wilson and Jungner criterion	What it requires	Why it matters
Accepted treatment exists	Effective intervention and facilities for diagnosis and treatment are available	Prevents harm from labeling without benefit; ensures screening changes outcomes
Important health problem	Condition has sufficient prevalence or severity to justify population screening	Rules out screening for trivial or exceedingly rare conditions with no public health impact
Recognizable early stage	Latent or early symptomatic phase exists and is detectable	Allows intervention before irreversible damage occurs
Suitable, acceptable, safe, inexpensive test	Test is valid, tolerable to the population, and affordable	Ensures feasibility and minimizes false positives, cost, and psychological harm

Watch out! The treatment criterion does not mean a cure must exist. It means an accepted intervention—which may be disease-modifying therapy, early supportive care, or preventive measures—must be available and shown to improve outcomes when initiated earlier than would occur without screening. The SMA example shows that the bar is "effective intervention," not "complete cure."

Key point! When a question asks about Wilson and Jungner criteria, the correct option will almost always reflect one of these four pillars: important health problem, accepted treatment, recognizable early stage, or suitable/acceptable/inexpensive test. Options that describe rarity, cost-blind accuracy, or absence of an early stage are designed to test whether you recognize the inverse of the actual principles. The historical and contemporary literature consistently returns to treatment availability as the pivotal ethical condition for screening ^[1][2][3].

```